48.68
price down icon0.37%   -0.18
pre-market  시장 영업 전:  47.82   -0.86   -1.77%
loading
전일 마감가:
$48.86
열려 있는:
$48.95
하루 거래량:
2.25M
Relative Volume:
0.77
시가총액:
$118.24B
수익:
$43.23B
순이익/손실:
$6.79B
주가수익비율:
12.15
EPS:
4.0051
순현금흐름:
$9.17B
1주 성능:
-1.72%
1개월 성능:
-6.24%
6개월 성능:
-4.23%
1년 성능:
+3.60%
1일 변동 폭
Value
$48.53
$49.08
1주일 범위
Value
$47.80
$49.24
52주 변동 폭
Value
$44.62
$60.12

사노피 ADR Stock (SNY) Company Profile

Name
명칭
Sanofi Adr
Name
전화
-
Name
주소
-
Name
직원
82,878
Name
트위터
@sanofi
Name
다음 수익 날짜
2025-10-24
Name
최신 SEC 제출 서류
Name
SNY's Discussions on Twitter

SNY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
SNY
Sanofi Adr
48.68 118.68B 43.23B 6.79B 9.17B 4.0051
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,027.51 903.41B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
211.58 505.98B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
223.32 395.86B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.57 253.97B 54.45B 14.42B 17.15B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
100.30 245.75B 63.90B 19.05B 13.05B 7.5596

사노피 ADR Stock (SNY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-12-09 다운그레이드 Guggenheim Buy → Neutral
2025-12-08 다운그레이드 JP Morgan Overweight → Neutral
2025-09-08 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-09-02 업그레이드 Deutsche Bank Hold → Buy
2025-08-08 업그레이드 JP Morgan Neutral → Overweight
2025-04-15 개시 Exane BNP Paribas Outperform
2025-03-21 개시 Goldman Neutral
2025-01-30 업그레이드 Deutsche Bank Sell → Hold
2024-07-26 재확인 Argus Buy
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2023-12-05 다운그레이드 JP Morgan Overweight → Neutral
2023-10-30 다운그레이드 Stifel Buy → Hold
2023-09-06 업그레이드 Berenberg Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-04-28 다운그레이드 Deutsche Bank Hold → Sell
2023-03-27 업그레이드 Barclays Equal Weight → Overweight
2022-12-13 재개 Morgan Stanley Overweight
2022-08-12 업그레이드 Deutsche Bank Sell → Hold
2022-08-09 다운그레이드 UBS Buy → Neutral
2022-05-23 개시 SVB Leerink Outperform
2021-09-27 업그레이드 SVB Leerink Mkt Perform → Outperform
2021-01-15 개시 Deutsche Bank Sell
2020-09-29 개시 Berenberg Hold
2020-03-17 업그레이드 Barclays Underweight → Equal Weight
2020-03-11 업그레이드 Goldman Neutral → Buy
2020-02-11 개시 SVB Leerink Mkt Perform
2020-01-06 업그레이드 JP Morgan Neutral → Overweight
2019-09-23 업그레이드 Guggenheim Neutral → Buy
2019-09-20 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-09-03 개시 Bernstein Outperform
2019-08-14 업그레이드 UBS Neutral → Buy
2018-12-11 업그레이드 Jefferies Hold → Buy
2018-11-01 업그레이드 Barclays Underweight → Equal Weight
2018-10-09 개시 Guggenheim Neutral
2018-09-10 업그레이드 BofA/Merrill Neutral → Buy
2018-08-10 업그레이드 Citigroup Neutral → Buy
2018-03-23 업그레이드 Liberum Hold → Buy
2018-01-23 다운그레이드 Barclays Equal Weight → Underweight
2017-12-06 다운그레이드 BofA/Merrill Buy → Neutral
2017-12-01 다운그레이드 Morgan Stanley Overweight → Underweight
2017-11-15 업그레이드 Barclays Underweight → Equal Weight
2017-08-30 업그레이드 HSBC Securities Reduce → Hold
모두보기

사노피 ADR 주식(SNY)의 최신 뉴스

pulisher
06:10 AM

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech

06:10 AM
pulisher
Dec 14, 2025

Sanofi (SNY) sees slight pessimism from analysts - MSN

Dec 14, 2025
pulisher
Dec 12, 2025

Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz

Dec 12, 2025
pulisher
Dec 11, 2025

Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs - Benzinga

Dec 11, 2025
pulisher
Dec 10, 2025

JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz

Dec 10, 2025
pulisher
Dec 09, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

​Sanofi (SNY) Completes the Acquisition of Vicebio - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm

Dec 09, 2025
pulisher
Dec 01, 2025

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 01, 2025
pulisher
Nov 28, 2025

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz

Nov 28, 2025
pulisher
Nov 26, 2025

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Nov 26, 2025
pulisher
Nov 25, 2025

SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Finviz

Nov 25, 2025
pulisher
Nov 25, 2025

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe - Sahm

Nov 25, 2025
pulisher
Nov 23, 2025

Bloom Energy-Aktie: Vorsicht geboten! - Finanztrends

Nov 23, 2025
pulisher
Nov 22, 2025

Abbott-Aktie: 21 Milliarden Dollar für neues Wachstum! - Finanztrends

Nov 22, 2025
pulisher
Nov 21, 2025

Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Sahm

Nov 21, 2025
pulisher
Nov 21, 2025

Wasserstoff-Aktien: Bloom Energy kollabiert erneut, Nel ASA gibt nicht auf und Primary Hydrogen meldet Fortschritte! - Finanztrends

Nov 21, 2025
pulisher
Nov 21, 2025

A Technical View of the Leifras Co Ltd ADR (LFS) - fostersleader.com

Nov 21, 2025
pulisher
Nov 17, 2025

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 17, 2025
pulisher
Nov 10, 2025

Why Roche Holding Stock Popped Today - Finviz

Nov 10, 2025
pulisher
Nov 07, 2025

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Finviz

Nov 07, 2025
pulisher
Oct 28, 2025

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm

Oct 28, 2025
pulisher
Oct 27, 2025

UPDATE - GlobeNewswire Inc.

Oct 27, 2025
pulisher
Oct 24, 2025

Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria

Oct 24, 2025
pulisher
Oct 24, 2025

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm

Oct 24, 2025
pulisher
Oct 22, 2025

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm

Oct 22, 2025
pulisher
Oct 17, 2025

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm

Oct 17, 2025
pulisher
Oct 17, 2025

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm

Oct 17, 2025

사노피 ADR (SNY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general PFE
$25.85
price up icon 0.19%
$120.40
price down icon 2.28%
$317.74
price up icon 0.11%
drug_manufacturers_general NVO
$50.18
price down icon 0.22%
drug_manufacturers_general MRK
$100.30
price up icon 1.30%
자본화:     |  볼륨(24시간):